Although HCT is an effective means at mitigating, or even reversing clinical phenotypes associated of GATA2 deficiency, the optimal timing of HCT, and choice of conditioning regimen, donor sources, and GVHD prophylaxis remain areas of active investigation. The gene discussed is GATA2; the disease is hyperinsulinemic hypoglycemia, familial, 4.